1628717-55-4
Chemical Structure
Vidoflufolastat
Synonym(s): CTT-1057
- CAS No.: 1628717-55-4
- Formula:C28H40FN4O14P
- Molecular Weight:706.61
IUPAC Name: (E)-3-(3-bromophenyl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one
InChIKey: IZLOSIXADNUSCM-ACRUOGEOSA-N
SMILES: OC(CC[C@@H](C(O)=O)NP(OCCC[C@@H](C(O)=O)NC(CC[C@@H](C(O)=O)NC(CCCCCNC(C1=CC=C(C=C1)F)=O)=O)=O)(O)=O)=O
Biological Activity: Vidoflufolastat (CTT-1057) is a PSMA inhibitor with an IC50 of 0.4 nM. Vidoflufolastat binds irreversibly to the active-site zinc ion through its phosphoramidate core, while its distal fluorobenzoyl ring interacts with the arene-binding site. Vidoflufolastat can be used in research on prostate cancer and Pseudomonas aeruginosa infection[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vidoflufolastat | Vidoflufolastat (CTT-1057) is a PSMA inhibitor with an IC50 of 0.4 nM. Vidoflufolastat binds irreversibly to the active-site zinc ion through its phosphoramidate core, while its distal fluorobenzoyl ring interacts with the arene-binding site. Vidoflufolastat can be used in research on prostate cancer and Pseudomonas aeruginosa infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Werner RA, et al. F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics. 2020;10(1):1-16.
- [2]. Dannoon S, et al. Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. Journal of medicinal chemistry. 2016 Jun 23;59(12):5684-94.
- [3]. Rani A, et al. PSMA-Targeted 2-Deoxyglucose-Based Dendrimer Nanomedicine for the Treatment of Prostate Cancer. Biomacromolecules. 2024 Sep 09;25(9):6164-6180.
- [4]. Rosy JC, et al. l-Ornithine-N5-monooxygenase (PvdA) Substrate Analogue Inhibitors for Pseudomonas aeruginosa Infections Treatment: Drug Repurposing Computational Studies. Biomolecules. 2022 Jun 25;12(7):887.
